Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge

After a bruising financial third quarter in which net quarterly profit plunged 65%, Lupin reported “a successful outcome” for clinical trials of its rheumatoid arthritis drug etanercept, its first biosimilar product for the global market.

Jigsaw
LUPIN REPORTED A WEAK QUARTER BUT IS UPBEAT ABOUT ITS BIOSIMILARS PORTFOLIO

Developing etanercept - a copycat of biotech giant Amgen Inc.’s blockbuster drug Enbrel - with Japanese joint-venture partner Yoshindo, has been part of Lupin Ltd.’s stepped-up transition to complex generics, speciality medicines and biosimilars to generate new revenue sources that go beyond an increasingly congested and competitive plain-vanilla generic market. Lupin is seen by analysts as playing catch-up with its Indian peers in building a complex generic pipeline.

YLB, Lupin’s and Yoshindo’s joint venture, reported a “successful outcome” from its global Phase III clinical trial of etanercept involving...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.